“…GTR was available for n=8257 patients (Table 3). Using the fixed-effect model, the pooled rate of GTR among all studies was 71.0% (95%CI: 69.9–72.1%, I 2 =91.2%; P-heterogeneity<0.01 under the fixed-effect model (Table 4) [4–11, 15, 16, 18–23, 27, 30–33, 35, 37–39, 42, 44, 45, 47, 48, 50–56, 59, 64, 68, 70, 71, 74, 75, 78, 80, 82–84, 86–92]. When eTSS and mTSS were compared, GTR rate was significantly higher in eTSS (n=50 studies, GTR=74.0%, 95%CI: 72.6–75.3%, I 2 =92.1%; P-heterogeneity<0.01) than in mTSS (n=20 studies, GTR=66.4%, 95%CI: 64.5–68.2%, I 2 =84.0%; P-heterogeneity<0.01) (Figure 2).…”